Remove 2029 Remove Immunization Remove Pharmaceutical Companies
article thumbnail

GlobalData forecasts ADC NSCLC market to reach $3.9 bn in 2032

Express Pharma

Datroway is currently being evaluated in five Phase III clinical trials as a first-line therapy in combination with immune checkpoint inhibitors (ICIs), bispecific antibodies, and epidermal growth factor receptor inhibitors. AbbVie, AstraZeneca, and Daiichi Sankyo.